imalumab + 5-fluorouracil + leucovorin

Imalumab + 5-fluorouracil + leucovorin is an investigational combination therapy evaluated in metastatic colorectal cancer (mCRC) and other advanced solid tumors. - **Imalumab** is a fully human recombinant monoclonal antibody targeting oxidized macrophage migration inhibitory factor (**oxMIF**), a protein highly expressed in several cancers and implicated in tumor progression, anti-apoptosis, angiogenesis, and neovascularization. Imalumab binds oxMIF and blocks its activity, inhibiting downstream oncogenic cytokine secretion and tumor-supportive pathways, including ERK1/2 and AKT phosphorylation, with reported induction of apoptosis and interference with tumor cell survival and proliferation[1][2][3][5]. - **5-fluorouracil (5-FU)** is an antimetabolite chemotherapeutic that inhibits thymidylate synthase, disrupting DNA synthesis and leading to cytotoxicity in rapidly proliferating cells. - **Leucovorin (folinic acid)** potentiates 5-FU cytotoxicity by stabilizing its binding to thymidylate synthase, increasing efficacy. This combination was tested in patients with mCRC who had failed two or more prior treatment lines, aiming to improve progression-free survival and overall outcomes via synergistic antitumor activity and acceptable tolerability[2].

Other names

imalumab + 5-FU + leucovorinimalumab + fluorouracil + folinic acid